PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
15th Annual American Conference on Pharmacometrics (ACoP 2024) – November 10-13, 2024
Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemia
Presenter: Jack Shi
Session: Poster
Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia
Presenter: Jack Shi
Session: Poster
UBS Global Healthcare Conference – November 11-14, 2024
Type: Fireside Chat Presentation
Date/Time: November 12, 2024, 3:30 p.m. PST
TIDES Europe – Oligonucleotide and Peptide Therapeutics – November 12-14, 2024
Title: Novel TRiM™ Platform for Oligonucleotide Delivery to Trabecular Meshwork via Local Intracameral Administration
Date/Time: November 14, 2024, 14:00 CET
Presenter: Jing Chen
Session: Oligonucleotide Discovery, Preclinical and Clinical
American Heart Association (AHA) Scientific Sessions 2024 – November 16-18, 2024
Title: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)
Date/Time: November 16, 2024, 2:04 pm CST
Presenter: Gerald Watts
Session: Featured Science: Novel Approaches to Managing Lipid Risk
Title: Plozasiran and Triglyceride Levels in Hypertriglyceridemia: Long-Term Efficacy and Safety Data from Subjects in an Open-Label Extension Trial (MUIR and SHASTA-2 OLE)
Date/Time: November 18, 2024, 10:45 am CST
Presenter: Christie Ballantyne
Session: New Insights in Lipids and lipid lowering therapies
The Liver Meeting 2024 - American Association for the Study of Liver Diseases (AASLD) – November 15-19, 2024
Title: Long-Term Safety and Efficacy of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Enrolled in the Phase 2 Placebo-Controlled SEQUOIA Trial
Date/Time: November 18, 2024, 8:00 am PST
Presenter: Virginia Clark
Session: Metabolic and Genetic Disease
Title: Digital Image Quantification of Collagen Proportionate Area Correlates with METAVIR Fibrosis Stage and Liver Stiffness Measurement Via FibroScan® in Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Date/Time: November 18, 2024, 8:00 am PST
Presenter: Cynthia Behling
Session: Metabolic and Genetic Disease
Title: Concordance of Histological and Liquid Chromatography Mass Spectrometry-Based Intrahepatic Z-Alpha-1 Antitrypsin (Z-AAT) Burden Assessments in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Date/Time: November 18, 2024, 8:00 am PST
Presenter: Rohit Loomba
Session: Metabolic and Genetic Disease
Jefferies London Healthcare Conference – November 19-21, 2024
Type: Fireside Chat Presentation
Date/Time: November 20, 2024, 8:00 am GMT
Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
